Barber R, 2003
Barber R, 2003
Barber R, 2003
(Received in original form September 17, 2002; accepted in final form February 8, 2003)
Supported by NIGMS grant #5P50GM021681370013 (G.E.O.).
Correspondence and requests for reprints should be addressed to Grant OKeefe,
MD, University of Washington, Department of Surgery, Box 359796, Harborview
Medical Center, 325 Ninth Avenue, Seattle, WA 981042499. E-mail: gokeefe@
u.washington.edu
Am J Respir Crit Care Med Vol 167. pp 13161320, 2003
Originally Published in Press as DOI: 10.1164/rccm.200209-1064OC on February 13, 2003
Internet address: www.atsjournals.org
1317
Primer Sequences (5 to 3)
LBP-Pyro-For-biotin
CAGCCTGAACATCCACAGC
LBP-Pyro-Rev
LBP-Pyro-Seq
AAGAATGACTTGCGCACCTT
GCTGAGACTCAGGCCCTGGC
Cycling Conditions
95C for 5 min/35 cycles; 95C
for 30 s, 63C for 60 s, 72C
for 60 s/72C for 5 min.
NA
Pyrosequencing Analysis
All genotypes were determined by pyrosequencing analysis on a PSQ
96 Pyrosequencer (Pyrosequencing AB, Westborough, MA) according
to manufacturers specifications, and genotypes were resolved using PSQ
96 SNP Software, version 1.2 AQ. Each SNP was assayed with a specific
primer sequence (Table 1), which enabled the unambiguous scoring of
heterozygotes and alternate homozygotes (10). As a sequencing-based
technique, pyrosequencing is a rapid method that has been used for SNP
haplotyping and as a reliable alternative to microsatellite analysis for
chimerism (11, 12).
relative risk for severe sepsis with its associated 95% confidence interval
is also presented. We then conducted a logistic regression analysis, incorporating the LBP genotype in addition to the variables that we previously
identified to be risk factors for complicated sepsis. These variables
included age of 55 years or more, an arterial base deficit of 6 meq/L or
more measured between 624 hours after injury, and carriage of the
A-allele at the 308 position in the tumor necrosis factor- gene. The
adjusted odds ratios and associated 95% confidence intervals are also
presented. Adequate DNA was available from 151 of the 152 original
subjects, and these 151 are reported here.
RESULTS
We recruited injury victims admitted to the intensive care unit and included patients who were not brain dead, had an estimated injury severity
score of 16 or more, and were expected to be in the intensive care unit
for 24 hours or more. A detailed description of the study sample and
the end-point definitions has been previously published, and the important details are summarized here (13). Sepsis was defined according to
the ACCP/SCCM consensus definitions and required the simultaneous
presence of the systemic inflammatory response syndrome and a definite
source of infection based on a positive microbiologic culture (14). Severe
sepsis was defined as sepsis accompanied by organ failure such that the
organ failure was temporally related to sepsis. Organ failure was based
on our modification of the Multiple Organ Dysfunction Syndrome scoring
system, in which neurologic dysfunction is not scored and values measured
in the first 24 hours after injury are not included, to exclude transient
changes in organ function (13, 15). Septic shock required the presence
of a metabolic acidosis (a pH of 7.30 or less) or inotropic cardiac support
(excluding dopamine at 5 g/kg/minute or less) or vasopressor support
to maintain systolic blood pressure of 90 mm Hg or more. These criteria
are similar to those used by others in studies of genetic associations with
sepsis in adults (16).
In this report, our primary analysis was of the LPB genotype as a
risk factor for severe sepsis or septic shock that are referred to together
as complicated sepsis. We compared allele frequencies in patients with
and without complicated sepsis by Fishers exact test. The unadjusted
Figure 2. Nucleotide
and
protein sequences for the region surrounding nucleotide
291 of the LBP gene as reported by the NCBI SNP database (dbSNP). (A) The
wild-type sequence of LBP
gene (GenBank accession
numbers; NT_011362.7, BC022256, NM_004139, and AF10567). (B) Sequence of the LPB gene reported as wild-type by Hubacek and colleagues
(5). (C) Variant sequence of the LBP gene, as determined here by sequencing and pyrosequencing (GenBank accession number; M335533).
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 167 2003
TABLE 2. ALLELE FREQUENCIES IN TRAUMA PATIENTS
AND UNINJURED CONTROL SUBJECTS ACCORDING
TO ETHNICITY
White
T-allele
C-allele
African American
T-allele
C-allele
Hispanic
T-allele
C-allele
Trauma Patients
(n 145)
144 (84%)
28 (16%)
103 (90%)
11 (10%)
0.11
12 (50%)
12 (50%)
43 (48%)
47 (52%)
0.84
81 (86%)
13 (14%)
70 (90%)
8 (10%)
0.48
p Value
Patients with sox trauma who did not belong to the three indicated ethnic
groups were excluded. In both trauma patients (p 0.001) and uninjured control
subjects (p 0.001), the allele frequencies differed across ethnicity. Within each
ethnic group (p value shown for each group), there were no differences in allele
frequencies, and overall, after adjusting for ethnic group, there were no differences
(Mantel-Haenzel adjusted -square p value 0.88).
For the entire cohort, the frequency of the LBP 291 alleles did not
significantly differ between the patients with and without severe
sepsis (Table 2). When men and women were analyzed separately,
no association between carriage of the C-allele and severe sepsis
was observed.
Logistic regression revealed that carriage of the A-allele at the
LBP 291 SNP was not associated with an increased risk for severe
sepsis after trauma (odds ratio 1.157; 95% confidence interval,
0.4632.891). The inclusion of the LBP genotype did not markedly
alter the results of our previously reported analysis of this patient
cohort. This original report did not include the LBP SNP but did
include a SNP at nucleotide 308 of the tumor necrosis factor-
promoter and additional clinical risk factors for sepsis. The results
of the analysis, including the LBP SNP, are shown in Tables 3
and 4.
We conducted a series of additional, secondary analyses. First
DISCUSSION
By direct sequencing of the cloned DNA fragment containing the
proximal LPB gene coding region, we have determined that the
HpaII RFLP site, thought to be due to a T G SNP at the 292
nucleotide, is in fact the result of a T C SNP at the adjacent
291 position. Either of these substitutions would result in the generation of the HpaII restriction site, allowing differentiation of the
wild-type and variant alleles by RFLP analysis. However, this
method of detection is unable to distinguish the sequence of the
underlying polymorphism. This information is crucial, as the alternative SNPs would have substantially different effects on the resulting amino acid sequence. A T G transition at the 292 position
would be nonsynonymous and would result in the replacement of
cystine with glycine at amino acid residue 98. In contrast, the T
C substitution at 291 is silent, with both variants encoding the
amino acid proline at residue 97. We have used a third genotyping
method, pyrosequencing, to confirm our findings. This technique
directly sequences a short DNA fragment (510 bases), including
the polymorphic region of interest, and provides a visual display
of that sequence. Like RFLP, pyrosequencing requires prior knowledge of the nucleotide sequence adjacent to the SNP, but unlike
RFLP, pyrosequencing reveals the exact sequence change or polymorphism. The HpaII enzyme recognizes the nucleotide sequence
CCGG. Therefore, whereas either of the substitutions at nucleotide
291 or 292 would result in the generation of a restriction site that
appears identical by RFLP analysis, the SNPs would easily be
differentiated by sequencing or pyrosequencing. The results of
pyrosequencing correspond exactly to the results of sequencing in
our samples, identifying the SNP at the 291 position. Figure 3
illustrates the three variations on the nucleotide sequence of this
1319
No/Uncomplicated Sepsis
(n 114)
Severe Sepsis
(n 37)
77 (76)
37 (74)
24 (24)
13 (26)
0.456
58 (74)
25 (74)
83 (74)
20 (26)
9 (26)
29 (26)
0.927
19 (83)
12 (75)
31 (79)
4 (17)
4 (25)
8 (21)
0.563
All patients
Homozygous TT, n 101
C-allele carrier, n 50
Men
Homozygous TT, n 78
C-allele carrier, n 34
Total, n 112
Women
Homozygous TT, n 23
C-allele carrier, n 16
Total, n 39
p Value*
Definition of abbreviations: LBS lipopolysaccharide binding protein; SNP single nucleotide polymorphism.
* p values are for Fishers exact test.
p Value
Odds Ratio
0.755
0.000
1.2
5.8
0.532.9
2.215.0
0.003
0.075
0.094
3.8
2.6
2.6
1.69.4
0.917.6
0.857.9
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 167 2003
13.
References
1. Heumann D, Roger T. Initial responses to endotoxins and Gram-negative
bacteria. Clin Chim Acta 2002;323:5972.
2. Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison
JC, Tobias PS, Ulevitch RJ. Structure and function of lipopolysaccharide binding protein. Science 1990;249:14291431.
3. Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, Heshmati F, Cheval
C, Monchi M, Teboul JL, Riche F, et al. Association of TNF2, a TNFalpha promoter polymorphism, with septic shock susceptibility and
mortality: a multicenter study. JAMA 1999;282:561568.
4. Knight JC, Kwiatkowski D. Inherited variability of tumor necrosis factor
production and susceptibility to infectious disease. Proc Assoc Am
Physicians 1999;111:290298.
5. Hubacek JA, Stuber F, Frohlich D, Book M, Wetegrove S, Ritter M,
Rothe G, Schmitz G. Gene variants of the bactericidal/permeability
increasing protein and lipopolysaccharide binding protein in sepsis patients: gender-specific genetic predisposition to sepsis. Crit Care Med
2001;29:557561.
6. Clark JM. Novel non-templated nucleotide addition reactions catalyzed
by procaryotic and eucaryotic DNA polymerases. Nucleic Acids Res
1988;16:96779686.
7. Mead DA, Pey NK, Herrnstadt C, Marcil RA, Smith LM. A universal
method for the direct cloning of PCR amplified nucleic acid. Biotechnology 1991;9:657663.
8. Sambrook J, Gething MJ. Protein structure: chaperones, paperones. Nature 1989;342:224225.
9. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977;74:54635467.
10. Alderborn A, Kristofferson A, Hammerling U. Determination of singlenucleotide polymorphisms by real-time pyrophosphate DNA sequencing. Genome Res 2000;10:12491258.
11. Odeberg J, Holmberg K, Eriksson P, Uhlen M. Molecular haplotyping
by pyrosequencing. Biotechniques 2002;33:1104, 1106, 1108.
12. Hochberg EP, Miklos DB, Neuberg D, Eichner DA, McLaughlin SF,
Mattes-Ritz A, Alyea EP, Antin JH, Soiffer RJ, Ritz J. A novel rapid
single nucleotide polymorphism (SNP)-based method for assessment
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.